• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Dr. David Mischoulon on Natural Medications

Dr. David Mischoulon on Natural Medications

May 1, 2004
David Mischoulon, M.D., Ph.D. and Financial Disclosure
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
David Mischoulon, M.D., Ph.D.David Mischoulon, M.D., Ph.D. Assistant Professor of Psychiatry, Harvard Medical School Associate Director of Partners Healthcare Systems Center for Alternative Medicine in Psychiatry. Co-author Editor, Natural Medications for Psychiatric Disorders (Lippincott Williams & Wilkins, 2002) Financial Disclosure: Dr. Mischoulon is the recipient of research grants from Lichtwer and Cederroth (both makers of St. John’s Wort), and Laxdale Inc (omega-3).

TCR: My readers would be in interested in knowing a little bit about your background and how you came to be interested in natural medications for psychiatry.
Dr. Mischoulon: It was kind of serendipitous. I went to medical school at Boston University School of Medicine, where I got my M.D. and also a PhD in biochemistry. I did my residency in psychiatry at Mass General, and as chief resident, one of the duties was to run a lecture series on a particular subject of interest. Jerry Rosenbaum, who was then outpatient director and my supervisor as chief resident, had been recently given a book about herbal remedies for various medical indications. The book had a small chapter on psychiatric drugs, and Jerry thought that would be a great focus for a lecture series. At the time, I was also thinking about fellowship applications for continued work in depression research, and Maurizio Fava suggested that we do something with natural remedies. He and Jerry already had a grant on St. John's Wort for major depression and Maurizio thought that it might be a good niche for me. So, I did some more research on the topic and that is what I have been focusing on ever since.

TCR: Interesting. Have you found that you have been using natural medications in your practice?
Dr. Mischoulon: I use them, but I am careful about who I recommend them for. Since I work in a tertiary care center, I see more severely ill patients, and most of the research on these natural and complementary remedies suggests that they are most effective for people with milder illness. On the other hand, there are some very ill patients who have tried just about everything that is approved by the FDA, and either they just didn't respond to it or they couldn't tolerate the drugs because of side effects. Those are individuals that I might consider as candidates to use alternatives remedies.
“The theory is that humans, in order to function at their best, require a critical ratio of omega-3 to omega-6 fatty acids and perhaps the reason why there is so much depression in this country is because this ratio is skewed.”
- David Mischoulon

TCR: I know you've done some writing on omega-3 fatty acids. Can you explain what they are and how we should use them?
Dr. Mischoulon: The omega-3s are a family of essential fatty acids. They have a well-established body of evidence about their cardiovascular benefits. But more recently, there have been a number of studies suggesting that they may be effective for a number of different psychiatric conditions. Initially, Andrew Stoll found that a mixture of the omega-3s called EPA and DHA was effective for bipolar disorder (Arch Gen Psychiatry 1999; 56:407-412) and a couple of other groups have been looking at omega-3s for treatment of depression, borderline personality disorder, and schizophrenia. The preliminary results are encouraging and suggest that omega-3s may have a wide application in psychiatry, so I think it will be of much interest to psychiatrists to learn more about them.

TCR: There is also omega-6, isn't there?
Dr. Mischoulon: omega-6 fatty acids are found primarily in vegetable oils. In fact, one of the theories about the use of Omega-3's is that the American diet, the Western diet in general, tends to be very heavy on the Omega-6 fatty acids relative to the omega-3 fatty acids. For example, Americans tend to eat a lot of foods that contain highly processed vegetable oils, but relatively little fish. Historically, our primitive ancestors tended to eat more fish, so their diet was richer in omega-3's than omega-6's. So the theory is that humans, in order to function at their best, require a critical ratio of omega-3 to omega-6 and perhaps the reason why there is so much depression in this country is because this ratio is skewed. In theory, by correcting this imbalance, by giving omega-3 supplements, we might help to reverse some of these psychiatric disorders.

TCR: Are there any significant side effects of omega-3s?
Dr. Mischoulon: Yes, some patients have reported stomach upset and a fishy taste in the mouth when taking omega-3s. There have been some anecdotal reports of bipolar patients who take omega-3s without a concomitant mood stabilizer who have cycled into mania. In Dr. Stoll's study, he gave the omega-3 primarily as an adjunct to treatment. These patients were already taking mood stabilizers. In fact, most of the research on the omega-3s is as adjunct treatment, not as monotherapy. So, one of the things we emphasize is that bipolar patients who are interested in omega-3s should use them under a physician's supervision and should probably be on a mood stabilizer as well.

TCR: Given that there has been some evidence for omega-3's effectiveness in depression, bipolar disorder, borderline personality disorder, and schizophrenia, some clinicians would be inclined to recommend it to most of their patients, since those groups make up the majority of most psychiatric practices.
Dr. Mischoulon: Yes, a very good argument can be made for that. I find myself encouraging more of my patients to take omega-3 supplements because there is already the well-documented cardiovascular benefit. So just by taking omega-3 you are potentially improving your general health status. Most of the recent evidence on the omega-3s is that low doses (500 mg to 1000 mg) are effective.

TCR: And how much fish would you have to eat to get your daily dose of omega-3?
Dr. Mischoulon: If you are taking a gram a day of omega-3, that is probably equivalent to eating a salmon dinner three or four times a week. So, I tell my patients, "If you like fish, you certainly can benefit by eating more of it, but if we are looking at it from the standpoint of trying to attack a serious depression, then probably the supplementation is the way to go." It is easier to get a depressed patient to take a pill than to make a lifestyle change.

TCR: On the subject of depression, what's your opinion on St. John's Wort?
Dr. Mischoulon: There are thirty or so European studies that say it is effective, and there are about probably a half dozen or so American studies that are not very positive.

TCR: So the jury is still out?
Dr. Mischoulon: Yes. But to understand St. John's Wort in context, we have to know something about the FDA. For the FDA to approve an antidepressant, it requires two well-designed studies showing that it is truly better than placebo. Now that doesn't mean that there can't be studies saying that it is no better than placebo. Take Paxil (paroxetine), for example. Of the first nine controlled studies that were done, only two of them suggested that Paxil was better than placebo; the other seven showed that it was no better than placebo. The problem is that many negative studies don't get published, either because the manufacturer sponsored it and doesn't want to publish it, or because most journals don't think negative studies are "sexy" enough. So a lot of drugs that are widely considered to be effective may not be as effective as we think. So, what I think may be going on with St. John's Wort is the same thing -- that we happen to be getting some studies that are saying that it is not as effective as the earlier studies suggested. I think we have to take all of it with a grain of salt.

TCR: What about the controversial kava?
Dr. Mischoulon: Well, a couple of years ago there were at least two dozen reports of severe liver toxicity, including a couple of cases so extreme that a liver transplant was required. So that caused an uproar in the media and as a result of that kava has been banned in number of countries in Europe and I believe in Canada as well.

TCR: But it appears to still be available here.
Dr. Mischoulon: Yes, kava is still available in the U.S., and the FDA is investigating it. While the FDA does not formally regulate natural medications, if they have enough evidence that a certain medication could be harmful, whether it be natural or synthetic, they have the authority to remove it from the market. So, the FDA, could in theory, ban kava the way they banned ephedra earlier this year.

TCR: So, what do you tell your patients about kava?
Dr. Mischoulon: In general, I am not recommending it to anyone. What I do tell someone, if they have a compelling reason to take kava, is they should first always do so under a doctor's supervision. And, secondly, no one who has any history of liver disease or alcoholism or who is taking any drugs that are potentially toxic to the liver, like Depakote, should take kava; I think it is just too dangerous. Until we know more about the extent of this toxicity, I encourage people to be extremely careful.

TCR: Any parting words of wisdom on natural medications?
Dr. Mischoulon: Generally, what I say to everyone is that these medications are promising, and with time they will probably have an established niche in psychopharmacology. But for the time being, it is very important that people who use them do so under a doctor's supervision because we still don't know enough about their efficacy, as well as safety and drug-drug interactions. To prevent any tragic consequences like those we have seen with Kava or with some of the St. John's Wort interactions, it is always better to have a doctor on your team. That is what I recommend to everyone.
General Psychiatry
    Tcr 2004 05 qa david mischoulon 150x150
    David Mischoulon, M.D., Ph.D.

    More from this author
    Financial Disclosure

    More from this author
    www.thecarlatreport.com
    Issue Date: May 1, 2004
    SUBSCRIBE NOW
    Table Of Contents
    Mania from Alternative Meds?
    Dr. David Mischoulon on Natural Medications
    Sleep Naturally: Melatonin and Valerian
    Mood Disorders: Omega-3, SAMe, and Inositol
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.